Investor Relations
Invest in Quadrant Biosciences
Invest in Quadrant Biosciences
We just launched the world’s first epigenetic saliva test for autism
Investment opportunity available now.
We just launched the world’s first epigenetic saliva test for autism
Investment opportunity coming soon. Be first in line.
Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, the Clarifi™ diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges. Clarifi™ ASD, the first ever biological diagnostic aid for autism spectrum disorder, has just launched commercially in the U.S.
As seen on
News room
Press releases
Published research
Why invest in
Quadrant Biosciences?
World’s first epigenetic diagnostic aid for autism
We have just commercially launched the world’s first epigenetic diagnostic aid for autism.
Successfully raised over $30 million
We have successfully raised over $30 million from private investors who believe in what we are doing; and we have received nearly $3 million in funding awards from the NIH* and others.
Global leaders in the development of epigenetic diagnostics
We are among the global leaders in the development of epigenetic diagnostic tools for neurological conditions and have a diverse pipeline of products. Clarifi ASD is just the beginning. Several other products based on our epigenetic diagnostic science are currently under development including saliva tests for concussion and Parkinson’s disease.
Experienced management team
We have assembled a seasoned management team, as well as a experienced medical advisory board comprised of recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.
What is a Regulation A offering?
Regulation A is an exemption from SEC registration that allows early stage companies to raise funds for all types of investors, including “non-accredited” investors.
How & where do we purchase the shares?
The offering is now available. We are working with a company called Wefunder which provides a platform for you to learn about our company and the investment opportunity and, if interested, safely, simply, and securely make an investment. Visit our Wefunder page for more details.
What is the minimum investment?
We expect that the minimum investment will be $300, which is
100 shares at the $3.00/share price.
Learn more about
Clarifi ASD
Investment opportunity
The science behind Clarifi
Early diagnosis: parent perspective
Who we are
Meet the team
We have assembled a seasoned management team, as well as an experienced medical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.
Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.
Our research partners
We are privileged to have partnered with a number of outstanding research universities and organizations to help further our epigenetic research.
International
We have entered into a research partnership with EU Aims – a Europe-wide collaboration between organizations representing autistic people and their families, academia and industry.
The science behind the
Clarifi diagnostic platform
Innovative technology
Clarifi represents a new approach to autism diagnosis. It is based on RNA rather than DNA. Epigenetics rather than genetics.
Every gene that encodes a protein comes under the influence of non-coding RNAs, such as miRNA’s, in terms of whether it makes that protein and how much of that protein is made. These RNAs are involved in a wide range of biological processes in the body, making them a robust source of biomarkers for autism.
Using state of the art next-generation sequencing, researchers at SUNY Upstate Medical University, Penn State College of Medicine, and Quadrant Biosciences identified a broad panel of RNA features useful in diagnosing autism. These include both non-coding human RNAs such as miRNA and piRNA, as well as microbial RNAs associated with specific bacteria in the microbiome.
Product pipeline
Clarifi ASD is just the beginning. Several other products based on the Clarifi Epigenetic Diagnostic Platform are currently under development including saliva tests for concussions and Parkinson’s disease.
Quadrant Biosciences accomplishments
ClearEdge functional assessment system was named Best Sports Med Tech of 2018
Recognized as one of seven companies in the U.S. selected to participate in 2019-2020 Regulatory/Reimbursement Training Track (RTT) of the CAP program*
Recognized as among the most influential research studies presented at the International Congress of Parkinson's Disease and Movement Disorders in Nice, France in 2019
Recognized for having raised over $30 million to date from private investors
Published 18 papers supporting science behind the Clarifi Platform including autism, parkinson's, concussion, anorexia nervosa
Winner of the 2019 New York Technology Business of the Year award
Research partnerships with Penn State Health, Upstate Medical University, Baylor College of Medicine, University of Missouri, Cincinnati Children's Hospital and the Autism Treatment Network
Filed 29 patent applications for biomarker panels and diagnostic methods
$3 million in research grants awarded by the National Institutes of Health (NIH) and others*
Commercial release of Clarifi ASD, the world's first epigenetic saliva test that can aid the diagnosis of autism
Key autism statistics
Trending on social media
2020 Conference Schedule
- MAPS Spring 2020, Functional & Translational Medicine Conference – March 19th – 21st | Orlando, FL
- Nurse Practitioner Conference – March 25th – 28th | Long Beach, CA
- Any Baby Can – April 18th | Texas
- Society of Pediatric Nurses – April 22nd – 25th | Anaheim, CA
- Pediatric Academic Societies Meeting – April 29th – May 6th | Philadelphia, PA
- American College of Osteopathic Pediatricians – April 30th – May 3rd | Colorado Springs, CO
- Pri-Med West – May 6th – 9th | Anaheim, CA
- 2020 AANP – June 23rd – 28th | New Orleans, LA
- Integrative Medicine for Mental Health Conference – August 20th – 23rd | Chicago, IL
- FCAAP Future of Pediatrics – September 4th – 6th | Orlando, FL
- AAP 2020 – October 3rd – 6th | San Diego, CA
- Society of Developmental & Behavioral Pediatrics – October 9th – 12th | Austin, TX
- Texas Pediatric Society – October 15th – 18th | Galveston, TX
- Family Medicine Experience AAFP – October 13th – 17th | Chicago, IL
- OMED Annual Meeting – October 16th – 20th | Austin, TX
- Child Neurology Society Meeting – October 19th – 23rd | San Diego, CA
- American Academy of Child & Adolescent Psychiatry – October 19th – 24th | San Francisco, CA
What are people saying
“It gives you a head start. It gives you an opportunity to take advantage of new
resources. He’s a different kid because we
got the help early on.”
-Olivia, mom
“This test is quick, it is non-invasive and it is something that will give you the answer that you need.”
-Angela Saturno, AAPSA
“The saliva test has the advantage of being objective and does not depend on rating someone’s behavior at one particular point in time.”
-Dr. Frank Middleton
“This allows us to...identify changes in the levels of molecules which differentiate kids with autism from kids who have typical development.”
-Dr. Steven Hicks
“A test which can separate children who have screened positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”
-Dr. Daniel Coury
“If most children aren’t being diagnosed until after age four, we’re losing months if not years of intervention that can deliver benefits throughout their lives.”
-Thomas Frazier, PhD, Chief Science Officer, Autism Speaks
Charitable involvement
Giving back
We support a number of organizations including Autism Nature Trail, PKAN research, Autism Speaks, Echo Autism, Autism Treatment Center, & Any Baby Can.
Investments in Quadrant Biosciences are speculative and involve risks. Risks include but are not limited to, illiquidity, complete loss of capital, regulatory risks, and valuation risks. See the offering circular for a complete discussion of risks.
*This research is supported by the National Institutes of Health under Applications Number R42 MH111347-02A1; 5R42MH111347-03; and 3R42MH111347-02A1S1. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM HERE.
YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.
See the NCPS Offerings Disclosure here.
Securities offered through North Capital Private Securities, member FINRA/SIPC.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.